|
|
Vaccine Detail
|
Alpha-Galactosylceramide-Pulsed Autologous Dendritic Cells |
| Vaccine Information |
- Vaccine Name: Alpha-Galactosylceramide-Pulsed Autologous Dendritic Cells
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007238
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- GALC
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: The therapeutic vaccine is composed by DCs and 4TOO tumor cells (total of 106 cells, ratio 1:1), which were irradiated 30 Gy immediately before injection, combined with 2 μg/mouse of α-GalCer (KRN7000; Enzo Life Sciences, USA) added to the cell suspension prior to mice treatment (referred to as Mix + GalCer vaccine) (Escribà-Garcia et al., 2017).
- Description: A cancer vaccine comprised of autologous dendritic cells (DCs) pulsed with the marine sponge glycolipid alpha-galactosylceramide (alpha-GalCer) with potential immunostimulatory and antimetastatic activities. Upon administration, alpha-galactosylceramide-pulsed autologous dendritic cells may result in the activation and proliferation of a subset of endogenous natural killer T (NKT) cells, B cells, and CD4+ and CD8+ T cells, and the production of interferon-gamma and interleukin-12; these cascade events may result in a T helper-1 cell-biased proinflammatory antitumor immune response. The NKT cell ligand alpha-GalCer was originally isolated from the marine sponge Agelas mauritianusis. (NCIT_C78489).
This vaccine has been used in trials involving early stage NSCLC trials.(Toyoda et al., 2020)
|
| Host Response |
|
|
| References |
Escribà-Garcia et al., 2017: Escribà-Garcia L, Alvarez-Fernández C, Tellez-Gabriel M, Sierra J, Briones J. Dendritic cells combined with tumor cells and α-galactosylceramide induce a potent, therapeutic and NK-cell dependent antitumor immunity in B cell lymphoma. Journal of translational medicine. 2017; 15(1); 115. [PubMed: 28549432].
NCIT_C78489: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C78489]
Toyoda et al., 2020: Toyoda T, Kamata T, Tanaka K, Ihara F, Takami M, Suzuki H, Nakajima T, Ikeuchi T, Kawasaki Y, Hanaoka H, Nakayama T, Yoshino I, Motohashi S. Phase II study of α-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer. Journal for immunotherapy of cancer. 2020; 8(1); . [PubMed: 32188702].
|
|
